524 related articles for article (PubMed ID: 33050345)
1. The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.
Bukke VN; Archana M; Villani R; Romano AD; Wawrzyniak A; Balawender K; Orkisz S; Beggiato S; Serviddio G; Cassano T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050345
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.
Rodriguez-Perdigon M; Tordera RM; Gil-Bea FJ; Gerenu G; Ramirez MJ; Solas M
Hippocampus; 2016 Oct; 26(10):1303-12. PubMed ID: 27258819
[TBL] [Abstract][Full Text] [Related]
3. Amyloid beta peptides and glutamatergic synaptic dysregulation.
Parameshwaran K; Dhanasekaran M; Suppiramaniam V
Exp Neurol; 2008 Mar; 210(1):7-13. PubMed ID: 18053990
[TBL] [Abstract][Full Text] [Related]
4. Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease.
Caioli S; Severini C; Ciotti T; Florenzano F; Pimpinella D; Petrocchi Passeri P; Balboni G; Polisca P; Lattanzi R; Nisticò R; Negri L; Zona C
Neuropharmacology; 2017 Apr; 116():82-97. PubMed ID: 27989680
[TBL] [Abstract][Full Text] [Related]
5. Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications.
Pinky PD; Pfitzer JC; Senfeld J; Hong H; Bhattacharya S; Suppiramaniam V; Qureshi I; Reed MN
Neuroscientist; 2023 Aug; 29(4):461-471. PubMed ID: 35073787
[TBL] [Abstract][Full Text] [Related]
6. d-glutamate and Gut Microbiota in Alzheimer's Disease.
Chang CH; Lin CH; Lane HY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290475
[TBL] [Abstract][Full Text] [Related]
7. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
8. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
Mota SI; Ferreira IL; Rego AC
Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder.
Goodwani S; Saternos H; Alasmari F; Sari Y
Neurosci Biobehav Rev; 2017 Jun; 77():14-31. PubMed ID: 28242339
[TBL] [Abstract][Full Text] [Related]
10. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration.
Andersen JV; Markussen KH; Jakobsen E; Schousboe A; Waagepetersen HS; Rosenberg PA; Aldana BI
Neuropharmacology; 2021 Sep; 196():108719. PubMed ID: 34273389
[TBL] [Abstract][Full Text] [Related]
11. NCX1 and EAAC1 transporters are involved in the protective action of glutamate in an in vitro Alzheimer's disease-like model.
Magi S; Piccirillo S; Maiolino M; Lariccia V; Amoroso S
Cell Calcium; 2020 Nov; 91():102268. PubMed ID: 32827867
[TBL] [Abstract][Full Text] [Related]
12. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
13. [Glutamate and Alzheimer's disease].
Gazulla J; Cavero-Nagore M
Rev Neurol; 2006 Apr 1-15; 42(7):427-32. PubMed ID: 16602060
[TBL] [Abstract][Full Text] [Related]
14. Morphine induction of c-fos expression in the rat forebrain through glutamatergic mechanisms: role of non-n-methyl-D-aspartate receptors.
Garcia MM; Anderson AT; Edwards R; Harlan RE
Neuroscience; 2003; 119(3):787-94. PubMed ID: 12809699
[TBL] [Abstract][Full Text] [Related]
15. Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity.
Forest KH; Nichols RA
Trends Mol Med; 2019 Aug; 25(8):685-695. PubMed ID: 31248781
[TBL] [Abstract][Full Text] [Related]
16. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease.
Jacob CP; Koutsilieri E; Bartl J; Neuen-Jacob E; Arzberger T; Zander N; Ravid R; Roggendorf W; Riederer P; Grünblatt E
J Alzheimers Dis; 2007 Mar; 11(1):97-116. PubMed ID: 17361039
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.
Paula-Lima AC; Brito-Moreira J; Ferreira ST
J Neurochem; 2013 Jul; 126(2):191-202. PubMed ID: 23668663
[TBL] [Abstract][Full Text] [Related]
18. Impairments of glutamatergic synaptic transmission in Alzheimer's disease.
Zott B; Konnerth A
Semin Cell Dev Biol; 2023 Apr; 139():24-34. PubMed ID: 35337739
[TBL] [Abstract][Full Text] [Related]
19. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease.
Zumkehr J; Rodriguez-Ortiz CJ; Cheng D; Kieu Z; Wai T; Hawkins C; Kilian J; Lim SL; Medeiros R; Kitazawa M
Neurobiol Aging; 2015 Jul; 36(7):2260-2271. PubMed ID: 25964214
[TBL] [Abstract][Full Text] [Related]
20. Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling.
Liu Y; Wang S; Kan J; Zhang J; Zhou L; Huang Y; Zhang Y
Curr Neuropharmacol; 2020; 18(4):260-276. PubMed ID: 31686629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
